Viibryd
通用名称
vilazodone hydrochloride
儿科标签批准日期
2020/1/31 0:00:00
特定指示/秒
Major depressive disorder (MDD)
标签更改摘要
- Safety and effectiveness have not been established in pediatric patients for the treatment of MDD. - Efficacy was not demonstrated in two adequate and well controlled, 8-week studies including a total of 1002 pediatric patients ages 7 - years to 17 years of age with MDD. The following adverse reactions were reported in at least 5% of pediatric patients treated with - VIIBRYD and occurred at a rate at least twice that for pediatric patients receiving placebo: nausea, vomiting, diarrhea, abdominal - pain/discomfort, and dizziness. - Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients
治疗类别
N/A
立法类型
PREA + BPCA
产品说明书链接
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:国家药品监督管理局| 国家中医药管理局| SDA药品评审中心| 医加医疗器械| 膏药生产厂家| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:33068302000535
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3